Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding AG    ROG   CH0012032048


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Roche : Genentech Provides Topline Results From Investigator-Led Phase II/III Trial With Gantenerumab in Rare Inherited Form of Alzheimer's Disease

share with twitter share with LinkedIn share with facebook
share via e-mail
02/11/2020 | 09:49am EDT

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the gantenerumab arm of the Phase II/III DIAN-TU-001 study did not meet its primary endpoint in people who have an early-onset, inherited form of Alzheimer's disease (AD).

This form of AD, known as autosomal dominant AD (ADAD), accounts for less than 1% of all cases of the disease. The study, sponsored by Washington University School of Medicine in St. Louis, did not show a significant slowing of the rate of cognitive decline in people treated with investigational medicine gantenerumab as measured by the novel DIAN Multivariate Cognitive Endpoint, compared with placebo. Overall, gantenerumab's safety profile in DIAN-TU-001 was consistent with that from other clinical trials of the investigational medicine and no new safety issues were identified.

Genentech and Roche are conducting additional analyses to understand the totality of the gantenerumab data from the study, in collaboration with Washington University School of Medicine. Data will be presented at the AAT-AD/PD Focus meeting in April 2020.

'We are very grateful to all those involved in this study and hope the data can further contribute to the science and collective understanding of this complex disease,' said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. 'Although DIAN-TU didn't reach its primary endpoint, the trial represents the first of its kind and a bold undertaking by all partners involved. Given its experimental nature, we are unable to draw firm conclusions about the impact of gantenerumab in autosomal dominant Alzheimer's disease. This outcome does not reduce our confidence in the ongoing Phase III GRADUATE clinical program.'

Gantenerumab, a late-stage investigational medicine, continues to be studied in two large global Phase III studies (GRADUATE 1 and 2) in the broader population of people with AD that is not directly caused by gene mutations (sporadic AD). Every person with ADAD who received gantenerumab in DIAN-TU-001 started on a lower dose and only started titrating to a fivefold higher target dose approximately halfway through the trial, prompted by learnings from other studies of gantenerumab. The GRADUATE studies have been designed from the outset to maximize exposure to gantenerumab, bringing all patients to target dose with minimal or no dose interruption within the study period.

Genentech and Roche's AD pipeline spans investigational medicines for different targets, types and stages of AD. In addition to the gantenerumab program, Genentech and Roche are evaluating semorinemab in Phase II studies in sporadic AD. Crenezumab also continues to be studied in the Alzheimer's Prevention Initiative Phase II trial in ADAD.

About the DIAN-TU-001 study

DIAN-TU-001 is a Phase II/III study sponsored by Washington University School of Medicine in St. Louis, United States. The study tested two investigational therapies compared to placebo (Genentech and Roche's gantenerumab and Eli Lilly and Company's solanezumab) to determine if either of these treatments could slow the rate of cognitive decline and improve disease-related biomarkers in people who are known to have a genetic mutation for inherited AD. The primary outcome measure for the study - the DIAN Multivariate Cognitive Endpoint - is a novel outcome measure designed to assess cognitive performance in people with ADAD.

The study followed 194 participants for up to 7 years; the average was about 5 years. Fifty-two people were randomized to active gantenerumab in the study. All participants came from families that carry a genetic mutation that causes inherited AD. The small study included people who did not yet have symptoms of AD at the time of enrollment as well as people who already had mild symptoms of the disease. There are 24 study centers worldwide for DIAN-TU-001, across the United States, Australia, Canada, France, Spain and the United Kingdom.

In the DIAN-TU-001 study, the most common adverse events reported more frequently with gantenerumab than placebo were injection-site reactions, infection of the nose and throat (nasopharyngitis), and amyloid-related imaging abnormalities (ARIA), manifesting as cerebral edema or microhemorrhages. The majority of ARIA findings were asymptomatic; if symptoms occurred, they were mild in nature and resolved.

About autosomal dominant Alzheimer's disease

Autosomal dominant AD (ADAD; also known as familial AD or dominantly-inherited AD [DIAD]) is a rare, inherited form of AD caused by single gene mutations in the APP, PSEN1 or PSEN2 genes. Less than 1% of all AD cases worldwide are thought to be caused by genetic mutations. It usually has a much earlier onset than the more common sporadic AD, with symptoms developing in people in their 30s to 60s. If an individual has one of these mutations, there is a 50% chance they will pass it on to each of their children.

About gantenerumab

Gantenerumab is an investigational medicine designed to bind to aggregated forms of beta-amyloid and remove beta-amyloid plaques, a pathological hallmark of AD thought to lead to brain cell death. Previous clinical studies of gantenerumab showed beta-amyloid plaque lowering in people with the more common form of AD that is not directly caused by gene mutations. The clinical significance of this effect is being investigated in two Phase III studies (GRADUATE 1 and 2), which are assessing the safety and efficacy of gantenerumab for the treatment of people with sporadic AD. The GRADUATE program is currently enrolling more than 2,000 patients in up to 350 study centers in more than 30 countries worldwide.

About Genentech in neuroscience

Neuroscience is a major focus of research and development at Genentech and Roche. The company's goal is to develop treatment options based on the biology of the nervous system to help improve the lives of people with chronic and potentially devastating diseases. Genentech and Roche have more than a dozen investigational medicines in clinical development for diseases that include multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer's disease, Huntington's disease, Parkinson's disease and autism.

About Genentech

Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions.


Tel: (650) 467-6800

(C) 2020 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ROCHE HOLDING AG
04:51aROCHE HOLDINGS AG : Goldman Sachs keeps its Buy rating
04:10aROCHE : FDA's Coronavirus Triage – How Pharma Can Work With The Agency To ..
04:08aROCHE : Invitation to Roche's Virtual Event “Digital technology and advanc..
04/06ROCHE HOLDINGS AG : Buy rating from Deutsche Bank
04/06ROCHE : UC Davis Health speeds up COVID-19 testing
04/03ROCHE HOLDINGS AG : Barclays remains its Buy rating
04/03ROCHE : Pay The Correct SPC Fee Or Risk Expiry Ahead Of Time!
04/01ROCHE HOLDINGS AG : JP Morgan maintains a Buy rating
04/01CHUGAI PHARMACEUTICAL : Files for Foundation One Liquid CDx Aiming to Provide Bl..
04/01CHUGAI PHARMACEUTICAL : Announces DIGITAL VISION 2030 to Accelerate Digital Tran..
More news
Financials (CHF)
Sales 2020 62 429 M
EBIT 2020 23 255 M
Net income 2020 15 038 M
Finance 2020 3 115 M
Yield 2020 2,91%
P/E ratio 2020 18,1x
P/E ratio 2021 17,1x
EV / Sales2020 4,34x
EV / Sales2021 4,11x
Capitalization 274 B
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 353,94  CHF
Last Close Price 322,70  CHF
Spread / Highest target 25,5%
Spread / Average Target 9,68%
Spread / Lowest Target -27,5%
EPS Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
Paul Bulcke Non-Executive Director
André S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG2.77%277 060
JOHNSON & JOHNSON-8.02%345 705
MERCK & CO., INC-11.70%195 141
NOVARTIS-9.36%187 703
PFIZER, INC.-11.77%181 075
NOVO NORDISK A/S8.04%141 503